查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1320065

肺動脈高血壓市場，依藥物類別分佈 - 全球預測 2023-2030

Pulmonary Arterial Hypertension Market by Drug Class, Distribution - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

按藥物類別分類的全球肺動脈高血壓市場預計將在 2023 年大幅成長，達到 90.8687 億美元，年複合成長率為 6.57%，到 2030 年將達到 142.9700 億美元。

FPNV定位矩陣

FPNV定位矩陣對於按藥物類別評估全球肺動脈高血壓市場至關重要。透過檢驗業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.按藥物類別分類的肺動脈高血壓的全球市場規模和預測是多少？

2.在預測期內，COVID-19 塑造全球肺動脈高血壓藥物類別市場的阻礙因素與影響有哪些？

3.預測期內，全球肺動脈高血壓市場依藥物類別分類有哪些產品/細分市場/應用/領域值得投資？

4.依藥物類別分類，全球肺動脈高血壓市場的競爭策略為何？

5.全球肺動脈高血壓市場按藥物類別分類的技術趨勢和法律規範是什麼？

6.依藥物類別分類，全球肺動脈高血壓市場主要供應商的市佔率為何？

7. 哪些型態和策略性措施被認為適合進入全球肺動脈高血壓藥物類別市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 促進因素
      • 心血管疾病盛行率上升和老年人口增加
      • 政府配合措施罕見疾病藥物研發
      • 正在開發的肺部治療臨床藥物
    • 抑制因素
      • 患者對不同藥物類別肺動脈高血壓的認知有限
      • 肺部疾病的診斷和治療費用較高
    • 機會
      • 治療肺動脈高血壓的高級口服藥物（依藥物類別）
      • 生物製造商和新基因療法等治療技術的進步
    • 任務
      • 臨床藥品核准流程複雜
  • 市場趨勢
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化

第6章 高壓市場

  • 鈣通道阻斷劑
  • 內皮素受體拮抗
  • 磷酸二酯酶5
  • 前列環素和前列環素類似物

第7章 高壓市場分佈

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第8章 按藥物類別分類的美洲肺動脈高血壓市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章 按藥物類別分類的亞太肺動脈高血壓市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲肺動脈高血壓市場（依藥物類別）

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭形勢

  • FPNV定位矩陣
  • 市佔率分析：主要企業
  • 競爭情境分析：主要企業

第12章上市公司名單

第13章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-030D347B0AE5

The Global Pulmonary Arterial Hypertension Market is forecasted to grow significantly, with a projected USD 9,086.87 million in 2023 at a CAGR of 6.57% and expected to reach a staggering USD 14,209.70 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Pulmonary Arterial Hypertension Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Pulmonary Arterial Hypertension Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Class, market is studied across Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5, and Prostacyclin & Prostacyclin Analog. The Prostacyclin & Prostacyclin Analog is projected to witness significant market share during forecast period.

Based on Distribution, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Hospital Pharmacy is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Pulmonary Arterial Hypertension Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Pulmonary Arterial Hypertension Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pulmonary Arterial Hypertension Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pulmonary Arterial Hypertension Market?

4. What is the competitive strategic window for opportunities in the Global Pulmonary Arterial Hypertension Market?

5. What are the technology trends and regulatory frameworks in the Global Pulmonary Arterial Hypertension Market?

6. What is the market share of the leading vendors in the Global Pulmonary Arterial Hypertension Market?

7. What modes and strategic moves are considered suitable for entering the Global Pulmonary Arterial Hypertension Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Pulmonary Arterial Hypertension Market, by Drug Class, 2022 vs 2030
  • 4.3. Pulmonary Arterial Hypertension Market, by Distribution, 2022 vs 2030
  • 4.4. Pulmonary Arterial Hypertension Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cardiovascular diseases and the growing geriatric population
      • 5.1.1.2. Supportive government initiatives for the development of orphan drugs
      • 5.1.1.3. Clinical drugs in pipeline for pulmonary treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness about presence of pulmonary arterial hypertension among patients
      • 5.1.2.2. High diagnosis & treatment cost of pulmonary disorders
    • 5.1.3. Opportunities
      • 5.1.3.1. Advance oral drugs for pulmonary arterial hypertension
      • 5.1.3.2. Technology advancement such as biomaker and new gene therapy for the treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Complicated process of clinical approval of drugs
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Pulmonary Arterial Hypertension Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Calcium Channel Blocker
  • 6.3. Endothelin Receptor Antagonists
  • 6.4. Phosphodiesterase 5
  • 6.5. Prostacyclin & Prostacyclin Analog

7. Pulmonary Arterial Hypertension Market, by Distribution

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Online Pharmacy
  • 7.4. Retail Pharmacy

8. Americas Pulmonary Arterial Hypertension Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Pulmonary Arterial Hypertension Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Pulmonary Arterial Hypertension Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. PULMONARY ARTERIAL HYPERTENSION MARKET RESEARCH PROCESS
  • FIGURE 2. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2022 VS 2030
  • FIGURE 3. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
  • FIGURE 5. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
  • FIGURE 6. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. PULMONARY ARTERIAL HYPERTENSION MARKET DYNAMICS
  • FIGURE 8. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. PULMONARY ARTERIAL HYPERTENSION MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. PULMONARY ARTERIAL HYPERTENSION MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. PULMONARY ARTERIAL HYPERTENSION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 5. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE 5, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN & PROSTACYCLIN ANALOG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 10. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 99. PULMONARY ARTERIAL HYPERTENSION MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 100. PULMONARY ARTERIAL HYPERTENSION MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 101. PULMONARY ARTERIAL HYPERTENSION MARKET LICENSE & PRICING